This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Arno Therapeutics To Present Data On Two Potential Predictive Biomarkers At The San Antonio Breast Cancer Symposium 2013

Stocks in this article: ARNI

- Data Expand Support for Development of Diagnostic to Identify Patients With Biomarkers of Anti-Progestin and Anti-Estrogen Activity -

- Bolster Findings Presented at ASCO and ECC 2013 -

Poster Session 6 Saturday, December 14; 7:30 - 9:00 a.m. CT Abstract #1282 Poster #P6-05-13

FLEMINGTON, N.J., Dec. 14, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that data from a biomarker study supporting its lead compound onapristone will be presented at a poster session at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) annual meeting, being held December 10-14, 2013 in San Antonio, Texas. The symposium is hosted by the American Association for Cancer Research, The Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine.

Findings from the study "Tumor and Cellular Distribution of Activated Forms of ERα and PR in Breast Cancers" (Abstract #1282) will be presented during Poster Session 6 on Tumor Cell and Molecular Biology: Biomarkers on Saturday, December 14 from 7:30 – 9:00 a.m. CT in Exhibit Hall C of the Henry B. Gonzalez Convention Center. Data analysis from primary breast cancers further support the development of a diagnostic test to identify patient tumors with activated progesterone receptor (APR) and activated estrogen receptor (AER) as potential biomarkers of anti-progestin and anti-estrogen activity, respectively.

Onapristone is an oral, anti-progestin hormone blocker that has been shown to have anti-tumor activity in breast cancer. Onapristone appears to have a unique ability to block the APR, which is believed to be a mechanism that may inhibit the growth of breast, endometrial and other tumors. APR has the potential to function as a biomarker of anti-progestin activity.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs